Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | Artículo científico |
| Langue: | en |
| Publié: |
Carbohydrate polymers
2026
|
| Sujets: | |
| Accès en ligne: | https://pubmed.ncbi.nlm.nih.gov/41943296/ |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1868266064342679552 |
|---|---|
| author | Wang, Hui Yu, Haoyu Yang, Yan Fu, Mengying Geng, Lihua Wang, Jing Yue, Yang Zhang, Quanbin Wu, Ning |
| author_facet | Wang, Hui Yu, Haoyu Yang, Yan Fu, Mengying Geng, Lihua Wang, Jing Yue, Yang Zhang, Quanbin Wu, Ning Wang, Hui Yu, Haoyu Yang, Yan Fu, Mengying Geng, Lihua Wang, Jing Yue, Yang Zhang, Quanbin Wu, Ning |
| collection | PubMed - marine biology |
| contents | Synergistic induction of immunogenic cell death and tumor microenvironment remodeling by biotinylated marine polysaccharide nanoparticles for enhanced colorectal cancer therapy. Wang, Hui Yu, Haoyu Yang, Yan Fu, Mengying Geng, Lihua Wang, Jing Yue, Yang Zhang, Quanbin Wu, Ning Polysaccharides Tumor Microenvironment Humans Colorectal Neoplasms Animals Nanoparticles Immunogenic Cell Death Oxaliplatin Mice Chitosan Antineoplastic Agents HCT116 Cells HT29 Cells Mice, Inbred BALB C Drug Carriers Tumor heterogeneity, immunosuppression, and frequent adverse effects present major challenges in colorectal cancer therapy. Although the combination of oxaliplatin (OXA, chemotherapy) and fruquintinib (FRU, antiangiogenic) shows clinical promise, their divergent physicochemical properties and inadequate tumor selectivity lead to suboptimal efficacy and systemic toxicity. To overcome the challenge, we developed a tumor-targeted nanosystem based on chitosan and fucoidan for co-delivery of hydrophilic oxaliplatin and hydrophobic fruquintinib (CS-Arg/Fuc-Bio@OF). The nanoparticle leverages the inherent P-selectin affinity of fucoidan and active targeting given by biotin modification to achieve precise tumor accumulation and microenvironment-responsive drug release. In vitro studies demonstrated that CS-Arg/Fuc-Bio@OF effectively eliminated HCT116 and HT29 cancer cells by inducing robust immunogenic cell death (ICD) and exerted potent anti-angiogenic effects. The combination of OXA-induced ICD with FRU-mediated angiogenesis suppression and polysaccharide-promoted immunomodulation synergistically reprogrammed the immunosuppressive tumor microenvironment, facilitating an effective anti-tumor immune response. In vivo, the nanoparticles significantly inhibited tumor growth and demonstrated good biosafety, with a hemolysis rate |
| format | Artículo científico |
| id | pubmed_41943296 |
| institution | PubMed |
| language | en |
| publishDate | 2026 |
| publisher | Carbohydrate polymers |
| record_format | pubmed |
| spellingShingle | Synergistic induction of immunogenic cell death and tumor microenvironment remodeling by biotinylated marine polysaccharide nanoparticles for enhanced colorectal cancer therapy. Wang, Hui Yu, Haoyu Yang, Yan Fu, Mengying Geng, Lihua Wang, Jing Yue, Yang Zhang, Quanbin Wu, Ning Polysaccharides Tumor Microenvironment Humans Colorectal Neoplasms Animals Nanoparticles Immunogenic Cell Death Oxaliplatin Mice Chitosan Antineoplastic Agents HCT116 Cells HT29 Cells Mice, Inbred BALB C Drug Carriers Synergistic induction of immunogenic cell death and tumor microenvironment remodeling by biotinylated marine polysaccharide nanoparticles for enhanced colorectal cancer therapy. Wang, Hui Yu, Haoyu Yang, Yan Fu, Mengying Geng, Lihua Wang, Jing Yue, Yang Zhang, Quanbin Wu, Ning Polysaccharides Tumor Microenvironment Humans Colorectal Neoplasms Animals Nanoparticles Immunogenic Cell Death Oxaliplatin Mice Chitosan Antineoplastic Agents HCT116 Cells HT29 Cells Mice, Inbred BALB C Drug Carriers Tumor heterogeneity, immunosuppression, and frequent adverse effects present major challenges in colorectal cancer therapy. Although the combination of oxaliplatin (OXA, chemotherapy) and fruquintinib (FRU, antiangiogenic) shows clinical promise, their divergent physicochemical properties and inadequate tumor selectivity lead to suboptimal efficacy and systemic toxicity. To overcome the challenge, we developed a tumor-targeted nanosystem based on chitosan and fucoidan for co-delivery of hydrophilic oxaliplatin and hydrophobic fruquintinib (CS-Arg/Fuc-Bio@OF). The nanoparticle leverages the inherent P-selectin affinity of fucoidan and active targeting given by biotin modification to achieve precise tumor accumulation and microenvironment-responsive drug release. In vitro studies demonstrated that CS-Arg/Fuc-Bio@OF effectively eliminated HCT116 and HT29 cancer cells by inducing robust immunogenic cell death (ICD) and exerted potent anti-angiogenic effects. The combination of OXA-induced ICD with FRU-mediated angiogenesis suppression and polysaccharide-promoted immunomodulation synergistically reprogrammed the immunosuppressive tumor microenvironment, facilitating an effective anti-tumor immune response. In vivo, the nanoparticles significantly inhibited tumor growth and demonstrated good biosafety, with a hemolysis rate |
| title | Synergistic induction of immunogenic cell death and tumor microenvironment remodeling by biotinylated marine polysaccharide nanoparticles for enhanced colorectal cancer therapy. |
| topic | Polysaccharides Tumor Microenvironment Humans Colorectal Neoplasms Animals Nanoparticles Immunogenic Cell Death Oxaliplatin Mice Chitosan Antineoplastic Agents HCT116 Cells HT29 Cells Mice, Inbred BALB C Drug Carriers |
| url | https://pubmed.ncbi.nlm.nih.gov/41943296/ |